Ribupatide
A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes
Fujian Shengdi Pharmaceutical Co · Phase 2 · Completed · Enrollment 249
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Treatment group A | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group B | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group C | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group D | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group E | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group F | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group G | Obesity or overweight | n/r | n/r | n/r | n/r |
| Treatment group H | Obesity or overweight | n/r | n/r | n/r | n/r |